The Disappointing Results of Two Drugs for Parkinson's

Parkinson's is a relentlessly progressive disease and while we're good at treating symptoms and signs, there's currently no established way of slowing down disease progression. One of the great hopes is that by targeting the underlying disease pathology, the pathophysiological process, we might be able to slow down disease progress. And one of the approaches that has been tested now in a number of trials is antibodies that specifically try to target the alpha-synuclein misfolding  and hopefully prevent them from happening. Two large studies, as you mentioned, both studying a monoclonal antibody, now being tested in large numbers of participants in a randomized controlled trial. Both studies were published in the New England